



UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024

June 6, 2024

-- Program to Highlight 12-Month Durability of Response Results from the Phase 3 ENVISION Pivotal Trial --

PRINCETON, N.J.--(BUSINESS WIRE)--Jun. 6, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today shared additional details about the upcoming ENVISION virtual data event on Thursday, June 13, 2024, at 11:00 a.m. Eastern Time. The event will focus on UGN-102 (mitomycin) for intravesical solution for patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

UroGen will provide 12-month durability of response results (secondary endpoint) from patients who exhibited a complete response (the primary endpoint) at three months following six weekly instillations of UGN-102. The program will also feature Key Opinion Leaders and a panel discussion on the treatment of LG-IR-NMIBC.

Please register for the webinar under the Events & Presentations section of the Company's Investor Relations site (<https://investors.urogen.com/events-and-presentations>).

Following the live audio webcast, a replay will be available on the Company's website (<https://urogen.com>).

About UGN-102

UGN-102 (mitomycin) for intravesical solution is an investigational drug formulation of mitomycin in Phase 3 development for the treatment of LG-IR-NMIBC. Utilizing UroGen's proprietary *RTGel*® technology, a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting. If approved, UGN-102 would be the first non-surgical option approved for primary treatment of LG-IR-NMIBC, a subset of bladder cancer characterized by high recurrence rates and multiple surgeries.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed *RTGel*® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. JELMYTO® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential for UGN-102 to be the first non-surgical option approved for primary treatment of LG-IR-NMIBC; the potential of UroGen's proprietary *RTGel* technology to improve therapeutic profiles of existing drugs; and UroGen's sustained release technology making local delivery potentially more effective as compared to other treatment options. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: preliminary results may not be indicative of results that may be observed in the future; results from the ENVISION trial may not be sufficient to support an NDA submission for UGN-102; even if an NDA for UGN-102 is accepted by the FDA, there is no guarantee that such NDA will be sufficient to support approval of UGN-102 on the timeframe expected, or at all; the timing and success of clinical trials and potential safety and other complications thereof; unforeseen delays that may impact the timing of progressing clinical trials and reporting data; the ability to obtain regulatory approval within the timeframe expected, or at all; the ability to maintain regulatory approval; complications associated with commercialization activities; the labeling for any approved product; competition in UroGen's industry; the scope, progress and expansion of developing and commercializing UroGen's product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; UroGen's ability to attract or retain key management, members of the board of directors and personnel; UroGen's *RTGel* technology may not perform as expected; UroGen may not successfully develop and receive regulatory approval of any other product that incorporates *RTGel* technology; UroGen's financial condition and need for additional capital in the future. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the SEC in May 13, 2024 (which is available at <http://www.sec.gov>), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240606674853/en/): <https://www.businesswire.com/news/home/20240606674853/en/>

INVESTOR CONTACT:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano
Director, Corporate Communications

cindy.romano@urogen.com
609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.